Home>>Signaling Pathways>> Others>> Renal Diseases>>p-Cresyl sulfate

p-Cresyl sulfate

Catalog No.GC17516

Protein-bound uremic retention solute

Products are for research use only. Not for human use. We do not sell to patients.

p-Cresyl sulfate Chemical Structure

Cas No.: 3233-58-7

Size Price Stock Qty
1mg
$50.00
In stock
5mg
$150.00
In stock
10mg
$245.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Product Documents

Quality Control & SDS

View current batch:

Protocol

Cell experiment [1]:

Cell lines

Human umbilical vein endothelial cells

Preparation method

Limited solubility. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.

Reaction Conditions

24 h

Applications

Without and with HSA, 10 mug/mL, 25 mug/mL and 50 mug/mL p-cresol induce a decrease in endothelial cell proliferation by 21%, 38% and 54%, respectively. Without HSA, endothelial wound repair in monolayers treated with p-cresol is prominently lower than in cells treated with control medium. 10 mug/mL, 25 mug/mL and 50 mug/mL p-cresol reduce endothelial wound repair by 19%, 28% and 40%, respectively. With HSA, only 50 mug/mL p-cresol prominently blocks endothelial wound repair.

Animal experiment [2]:

Animal models

Rat

Dosage form

Intravenously injection of p-cresol (10 mg/kg) in rats with normal and decreased renal function

Preparation method

Dissolved in isotonic saline

Applications

P-cresol was injected in mice with normal and decreased renal function, and compared the results with those obtained for creatinine (60 mg/kg) under similar conditions. In rats with decreased renal function, p-cresol serum concentration displays a minimal decline, in contrast to rats with normal renal function. In rats with normal renal function, 21.0±10.0% of the injected p-cresol was excreted in urine. In rats with renal failure, the amount is 6.7±7.5%.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

1. Dou L, Bertrand E, Cerini C, et al. The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney international, 2004, 65(2): 442-451.

2. Lesaffer G, De Smet R, D'Heuvaert T et al. Comparative kinetics of the uremic toxin p-cresol versus creatinine in rats with and without renal failure. Kidney Int. 2003 Oct; 64(4):1365-73.

Background

The p-Cresol is a protein-bound uremic retention solute 1.

Free p-Cresol was found to be a cardiovascular risk factor in non-diabetic hemodialysis patients. In patients with diabetes, the level of both free p-cresol and total p-cresol were markedly higher. In patients treated by hemodialysis, the levels of these two forms of p-cresol were also significantly higher than that of patients treated by hemodiafiltration. The univariate cox proportional hazard analysis showed that the concentration of free p-cresol was obviously associated with cardiovascular disease (CVD). Quite many patients with high free p-cresol concentrations had new fatal or non-fatal cardiovascular events. Besides that, p-cresol was also found to inhibit cell proliferation. It inhibited the proliferation of cultured endothelial cells by 26% without affecting cell viability. Moreover, p-cresol treatment reduced endothelial wound repair by 19%, 28% and 40% at concentrations of 10, 25 and 50 μg/ml, respectively 1,2.

References:
1. Meijers B K I, Bammens B, De Moor B, et al. Free p-cresol is associated with cardiovascular disease in hemodialysis patients. Kidney international, 2008, 73(10): 1174-1180.
2. Dou L, Bertrand E, Cerini C, et al. The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney international, 2004, 65(2): 442-451.

Chemical Properties

Cas No. 3233-58-7 SDF
Chemical Name p-tolyl hydrogen sulfate
Canonical SMILES CC1=CC=C(OS(O)(=O)=O)C=C1
Formula C7H8O4S M.Wt 188.2
Solubility ≥ 30.1mg/mL in DMSO, ≥ 50mg/mL in Water Storage Store at -20°C
General tips Please select the appropriate solvent to prepare the stock solution according to the solubility of the product in different solvents; once the solution is prepared, please store it in separate packages to avoid product failure caused by repeated freezing and thawing.Storage method and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored at -20°C, please use it within 1 month.
To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time.
Shipping Condition Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request.

Complete Stock Solution Preparation Table

Prepare stock solution
1 mg 5 mg 10 mg
1 mM 5.3135 mL 26.5675 mL 53.135 mL
5 mM 1.0627 mL 5.3135 mL 10.627 mL
10 mM 0.5313 mL 2.6567 mL 5.3135 mL
  • Molarity Calculator

  • Dilution Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
**When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / CoA (available online).

Calculate

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.

Reviews

Review for p-Cresyl sulfate

Average Rating: 5 ★★★★★ (Based on Reviews and 37 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for p-Cresyl sulfate

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.